Why BofA worries about Hims & Hers. Hims & Hers stock has been a mega-outperformer for investors, growing more than 600% over ...

Shares of Hims & Hers Health Inc ( HIMS 17.50%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...

Key Takeaways Shares of Hims & Hers Health touched a fresh record high in Wednesday trading after the company announced its ...

Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last three months.

BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...

By acquiring Sigmund NJ LLC, known as Trybe Labs, Hims & Hers will be able "to support at-home blood draws and more ...